- Home
- FISI vs ATXS Comparison
FISI vs ATXS Comparison
Compare FISI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FISI | ATXS |
|---|---|---|
| Founded | 1817 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.8M | 732.4M |
| IPO Year | 1999 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FISI | ATXS |
|---|---|---|
| Price | $31.89 | $12.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 6 |
| Target Price | ★ $33.50 | $24.33 |
| AVG Volume (30 Days) | 128.3K | ★ 1.5M |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,735,000.00 | $706,000.00 |
| Revenue This Year | $124.17 | N/A |
| Revenue Next Year | $6.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.97 | $3.56 |
| 52 Week High | $33.00 | $13.29 |
Technical Indicators
Market Signals| Indicator | FISI | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 62.11 |
| Support Level | $31.85 | $12.64 |
| Resistance Level | $32.72 | $13.00 |
| Average True Range (ATR) | 0.59 | 0.22 |
| MACD | -0.12 | -0.05 |
| Stochastic Oscillator | 49.31 | 62.96 |
Price Performance
Historical ComparisonAbout FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.